Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01174173 · ClinicalTrials.gov registry record · Phase 3
Ranolazine and Pulmonary Hypertension
A Phase 3 study, sponsored by Northwestern University.
- Completed
- Registry status
- Phase 3
- Development phase
- 11
- Enrollment target
NCT01174173 is a Phase 3 study that has completed, run by Northwestern University. The registered enrollment target is 11 participants.
The verdict
NCT01174173, a Phase 3 study, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 11 participants
- Enrollment target
Study Summary
The purpose of the study is to determine if the medication, ranolazine (study drug), can help improve blood flow to your heart, increase your exercise capacity and improve your quality of life (QOL). For this study, you will be asked to perform several tests in order to determine if your heart function, exercise capacity, chest pain and QOL have improved after 3 months of treatment with ranolazine. Ranolazine is approved by the U.S. Food and Drug Administration (FDA) for the treatment of angina.
Interventions
- DRUG Ranolazine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2010-06 |
| Est. Completion | 2014-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01174173
The ClinicalTrials.gov registry entry for NCT01174173 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ranolazine is the first listed.
NCT01174173 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01174173 about?
NCT01174173 is a clinical study titled "Ranolazine and Pulmonary Hypertension". The purpose of the study is to determine if the medication, ranolazine (study drug), can help improve blood flow to your heart, increase your exercise capacity and improve your quality of life (QOL). For this study, you will be asked to perform several tests in order to determine if your heart funct...
What is the current status of trial NCT01174173?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 11 participants. The study started on 2010-06. Estimated completion is 2014-10.
What interventions are being tested in trial NCT01174173?
The interventions under investigation include: Ranolazine (DRUG).
Who is sponsoring clinical trial NCT01174173?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.